These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 29429869)

  • 21. Implementation of wide-scale pharmacogenetic testing in primary care.
    Natasha Petry ; Baye J; Aifaoui A; Wilke RA; Lupu RA; Savageau J; Gapp B; Massmann A; Hahn D; Hajek C; Schultz A
    Pharmacogenomics; 2019 Aug; 20(12):903-913. PubMed ID: 31453774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetic insights into depression and antidepressant response: does sex matter?
    Pitychoutis PM; Zisaki A; Dalla C; Papadopoulou-Daifoti Z
    Curr Pharm Des; 2010; 16(20):2214-23. PubMed ID: 20459391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Personalise antidepressant treatment for unipolar depression combining individual choices, risks and big data (PETRUSHKA): rationale and protocol.
    Tomlinson A; Furukawa TA; Efthimiou O; Salanti G; De Crescenzo F; Singh I; Cipriani A
    Evid Based Ment Health; 2020 May; 23(2):52-56. PubMed ID: 31645364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders.
    Hess GP; Fonseca E; Scott R; Fagerness J
    Genet Res (Camb); 2015 Jun; 97():e13. PubMed ID: 26030725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advancing Pharmacogenomics from Single-Gene to Preemptive Testing.
    Haidar CE; Crews KR; Hoffman JM; Relling MV; Caudle KE
    Annu Rev Genomics Hum Genet; 2022 Aug; 23():449-473. PubMed ID: 35537468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-drug pairs across ambulatory care settings.
    Cicali EJ; Weitzel KW; Elsey AR; Orlando FA; Vinson M; Mosley S; Smith DM; Davis R; Drum L; Estores D; Franciosi JP; Hagen MG; Jerkins GJ; Mercado ES; Nainaparampil J; Padron A; Rosenberg EI; Wright A; Schmidt SO; Mathews CA; Cavallari LH; Johnson JA
    Genet Med; 2019 Oct; 21(10):2264-2274. PubMed ID: 30926959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms.
    Ruano G; Kost JA
    Pain Physician; 2018 Nov; 21(6):E611-E621. PubMed ID: 30508992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Precision psychiatry in clinical practice.
    Zanardi R; Prestifilippo D; Fabbri C; Colombo C; Maron E; Serretti A
    Int J Psychiatry Clin Pract; 2021 Mar; 25(1):19-27. PubMed ID: 32852246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression.
    Islam F; Gorbovskaya I; Müller DJ
    Adv Exp Med Biol; 2021; 1305():231-255. PubMed ID: 33834403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late-life depression: issues for the general practitioner.
    Van Damme A; Declercq T; Lemey L; Tandt H; Petrovic M
    Int J Gen Med; 2018; 11():113-120. PubMed ID: 29636629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [How Far is "Personalized Medicine" for Depression from Clinical Use?].
    Kato M
    Seishin Shinkeigaku Zasshi; 2016; 118(8):615-624. PubMed ID: 30620480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.
    Ji Y; Skierka JM; Blommel JH; Moore BE; VanCuyk DL; Bruflat JK; Peterson LM; Veldhuizen TL; Fadra N; Peterson SE; Lagerstedt SA; Train LJ; Baudhuin LM; Klee EW; Ferber MJ; Bielinski SJ; Caraballo PJ; Weinshilboum RM; Black JL
    J Mol Diagn; 2016 May; 18(3):438-445. PubMed ID: 26947514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimating optimal shared-parameter dynamic regimens with application to a multistage depression clinical trial.
    Chakraborty B; Ghosh P; Moodie EE; Rush AJ
    Biometrics; 2016 Sep; 72(3):865-76. PubMed ID: 26890628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacotherapy of major depression in late life: what is the role of new agents?
    Patel K; Abdool PS; Rajji TK; Mulsant BH
    Expert Opin Pharmacother; 2017 Apr; 18(6):599-609. PubMed ID: 28317392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Digital Health Applications for Pharmacogenetic Clinical Trials.
    Naik H; Palaniappan L; Ashley EA; Scott SA
    Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33114567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Letter to the Editor: CONVERGENCES AND DIVERGENCES IN THE ICD-11 VS. DSM-5 CLASSIFICATION OF MOOD DISORDERS.
    Cerbo AD
    Turk Psikiyatri Derg; 2021; 32(4):293-295. PubMed ID: 34964106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenomics in the era of next generation sequencing - from byte to bedside.
    Russell LE; Zhou Y; Almousa AA; Sodhi JK; Nwabufo CK; Lauschke VM
    Drug Metab Rev; 2021 May; 53(2):253-278. PubMed ID: 33820459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions.
    Reisberg S; Krebs K; Lepamets M; Kals M; Mägi R; Metsalu K; Lauschke VM; Vilo J; Milani L
    Genet Med; 2019 Jun; 21(6):1345-1354. PubMed ID: 30327539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetic considerations for late life depression therapy.
    Pitychoutis PM; Kokras N; Sanoudou D; Dalla C; Papadopoulou-Daifoti Z
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):989-99. PubMed ID: 23641676
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.